 |
||||
|
||||
|
||||
|
||||
Previous Article | Next Article
The Journal of Neuroscience, February 1, 1999, 19(3):940-947
Prostaglandin E2 Stimulates Amyloid Precursor Protein Gene Expression: Inhibition by Immunosuppressants
Robert K. K. Lee, Stefan Knapp, and Richard J. Wurtman Division of Health Sciences and Technology, Massachusetts Institute of Technology-Harvard University, Cambridge, Massachusetts 02139
Amyloid plaques that accumulate in the brains of patients with Alzheimer's disease (AD) are primarily composed of aggregates of amyloid peptides that are derived from the amyloid precursor protein (APP). Overexpression of APP in cell cultures increases the formation of amyloidogenic peptides and causes neurodegeneration and cognitive dysfunction in transgenic mice. We now report that activation of prostaglandin E2 (PGE2) receptors increases cAMP formation and stimulates overexpression of APP mRNA and holoprotein in primary cultures of cortical astrocytes. Levels of glial fibrillary acidic protein were also increased by PGE2 treatment, suggesting that these cultured astrocytes resemble reactive astrocytes found in vivo. The stimulation by PGE2 of APP synthesis was mimicked or blocked by activators or inhibitors, respectively, of protein kinase A. Actinomycin D or cycloheximide also inhibited the increase in APP holoprotein stimulated by PGE2. Treatment of astrocytes with 8-Bromo-cAMP or forskolin for 24 hr also stimulated APP overexpression in cultured astrocytes. The immunosuppressants cyclosporin A and FK-506 inhibited the increase in APP mRNA and holoprotein levels caused by PGE2 or by other treatments that elevated cellular cAMP levels; the inhibitory effect of FK-506 but not of cyclosporin A was attenuated by rapamycin. These results suggest that prostaglandins produced by brain injury or inflammation can activate APP transcription in astrocytes and that immunosuppressants may be used to prevent APP overexpression and possibly the pathophysiological processes underlying AD.
Key words: inflammation; cAMP; astrocytes; rapamycin; cyclosporin A; FK506
Copyright © 1999 Society for Neuroscience 0270-6474/99/193940-08$05.00/0
This article has been cited by other articles:
D. W. Shineman, B. Zhang, S. N. Leight, D. Pratico, and V. M.-Y. Lee
Thromboxane Receptor Activation Mediates Isoprostane-Induced Increases in Amyloid Pathology in Tg2576 Mice
J. Neurosci., April 30, 2008; 28(18): 4785 - 4794.
[Abstract] [Full Text] [PDF]
Y. Avramovich, T. Amit, and M. B. H. Youdim
Non-steroidal Anti-inflammatory Drugs Stimulate Secretion of Non-amyloidogenic Precursor Protein
J. Biol. Chem., August 23, 2002; 277(35): 31466 - 31473.
[Abstract] [Full Text] [PDF]
K. I. Andreasson, A. Savonenko, S. Vidensky, J. J. Goellner, Y. Zhang, A. Shaffer, W. E. Kaufmann, P. F. Worley, P. Isakson, and A. L. Markowska
Age-Dependent Cognitive Deficits and Neuronal Apoptosis in Cyclooxygenase-2 Transgenic Mice
J. Neurosci., October 15, 2001; 21(20): 8198 - 8209.
[Abstract] [Full Text] [PDF]
B. R. Lackey, S. L. Gray, and D. M. Henricks
Does the Insulin-Like Growth Factor System Interact with Prostaglandins and Proinflammatory Cytokines During Neurodegeneration?
Experimental Biology and Medicine, May 1, 2000; 224(1): 20 - 27.
[Abstract] [Full Text]
T. J. Montine, K. R. Sidell, B. C. Crews, W. R. Markesbery, L. J. Marnett, L. J. Roberts II, and J. D. Morrow
Elevated CSF prostaglandin E2 levels in patients with probable AD
Neurology, October 22, 1999; 53(7): 1495 - 1495.
[Abstract] [Full Text] [PDF]
D. M. Skovronsky, V. M.-Y. Lee, and D. Pratico
Amyloid Precursor Protein and Amyloid beta Peptide in Human Platelets. ROLE OF CYCLOOXYGENASE AND PROTEIN KINASE C
J. Biol. Chem., May 11, 2001; 276(20): 17036 - 17043.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|